FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert

Find Clinical Drug Pipeline Developments & Deals by Cerebral Therapeutics


All Data

Filters Filter refresh
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): D-Tryptophanol

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $35.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing January 07, 2020


            The funding will help the company to initiate Phase 2b clinical trial for the treatment of medically refractory epilepsy in 2020.